Nestle Health Science Signs a Worldwide Exclusive Agreement with VALBIOTIS to Develop and Commercialize TOTUM-63 for Reducing the Risk of T2D
Shots:
- VALBIOTIS to receive ~$5.1M up front- ~$67.7 as development & commercial milestones and royalties on sales of therapy. Nestle to get exclusive global rights to commercialize TOTUM-63 in the prediabetes and T2D market
- The companies will jointly deal with clinical development- regulatory matters- supply and commercialization of the therapy. Additionally- VALBIOTIS will supply TOTUM-63 to Nestle representing an extra source of revenue
- TOTUM-63 is a patented combination of 5 plant extracts- designed to reduce the risk of developing T2D on prediabetics and demonstrated reduction in fasting and 2hrs. blood sugar levels in its P-II study
Click here to read full press release/ article | Ref: Buisnesswire | Image: Nestle Health
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com